The Pharmaceutical Anti-Counterfeiting Technology Market Will Reach $6.5bn In 2020, A New Study Predicts

07 September 2018
Pharma

A new report by visiongain forecasts the world pharmaceutical anti-counterfeiting technology market will reach $6.5bn in 2020. That revenue prediction and others appear in Pharmaceutical Anti-Counterfeiting Technologies Market Forecast 2016-2026, published in April 2016. Visiongain is a business information publisher and consultancy in London, UK.

The analysis predicts the global pharmaceutical anti-counterfeiting technologies market will continue to grow at a CAGR of 13.6% from 2014-2020, driven by the barcode and RFID submarkets. In 2015, the barcode submarket held a higher market share than the RFID submarket. However, the RFID submarket will become the leading submarket in 2017.
Demand for the market will be fuelled by an increasing prevalence of illegal counterfeiting incidents. Pharmaceutical companies will increasingly identify the need to protect their intellectual property and brand integrity by marginalising the rise in counterfeit activity through the use of technology.
Robert King, a pharmaceutical and healthcare industry analyst in visiongain, said:
“The introduction of tougher criminal penalties for counterfeiters coupled with government involvement demanding e-pedigrees on all pharmaceutical products will help to expand the anti-counterfeiting technologies market. The increasingly global pharmaceutical supply chain will also act as a catalyst for growth in this market. China and India, for example, are among the largest exporters of pharma products; therefore growth in the anti-counterfeiting technologies market of these two big economies will boost the global market.
To implement anti-counterfeiting technologies on a global scale there must be cohesion between different national regulatory authorities. Cooperation between countries on an international level must improve – many are now working towards standardisation”.
This report investigates commercial trends and revenues of the pharmaceutical anti-counterfeiting technology market from 2016 to 2026, as well as including data from 2014/2015. This report discusses sales potentials of:

• The main submarkets of pharmaceutical anti-counterfeiting technology:
o Barcodes
o RFID
o Taggants
o Hologram/OVD
o Other

• 8 leading national markets:
o US
o Japan
o EU
o China
o Russia
o India
o Brazil
o Mexico

This report qualitatively discusses:

• 15 anti-counterfeiting technology companies (including financial information) such as:
o 3M
o Avery Dennison
o ThermoFisher
o Multi Packaging Solutions

• The current and incoming legislation on a national market scale for pharmaceutical anti-counterfeiting technology including:
o The US
o The EU
o Brazil
o Russia
o India

• Strengths, weaknesses, opportunities and threats of the pharmaceutical anti-counterfeiting market.

Recent News

Visiongain Publishes Viral Vectors & Plasmid DNA Manufacturing Market Report 2021-2031

Due to increases in the therapies in progress, the dosages provided, & the patient populations targeted, viral vector production capacity has become increasingly reduced in recent years. The condition is aggravated by COVID-19.

03 December 2020

Read

Visiongain Publishes Drugs of Abuse Testing Market Report 2021-2031

Drugs Abuse has risen very significantly in few last year as compared to previous once and expected to continuously rise over the forecast period. The increase in the drugs abuse creates a huge demand for the drugs of abuse testing products.

03 December 2020

Read

Visiongain Publishes Controlled Substance Market Report 2021-2031

Continuous increasing prevalence of chronic pain is increasing demand for controlled substance as treatment for Chronic pain. Due to which increasing prevalence of chronic pain around the world is working as a driver for the controlled substance market.

03 December 2020

Read

Visiongain Publishes Companion Animal Diagnostics Market Report 2021-2031

All regions are facing rapid growth in the companion animal population. Companion animal are at high risk of developing various diseases for which companion animal require timely diagnosis for the identification, detection and treatment for life causing diseases.

03 December 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever